Special Issue

Pituitary Tumors: New Insights into Molecular Features, Diagnosis and Therapeutic Targeting

Message from the Guest Editor

Recent progress in understanding the molecular features of pituitary adenomas, one of the most frequent intracranial tumors and neuroendocrine neoplasms affecting 1 in 1000 in the general population, allowed us to improve their classification, with an impact on the diagnosis and the prediction of targeted treatments. Pituitary tumorigenesis is driven by diverse mechanisms, including gene amplification, mutation, overexpression, down-regulation and epigenetic silencing, microRNA misexpression, cell cycle dysregulation, endocrine dysfunction, and others. A deep knowledge of each of these mechanisms, mainly achieved thanks to the use of animal models, is leading to the development of effective therapeutic strategies, even for the most aggressive subtypes, characterized by invasiveness, recurrence, and resistance to conventional treatment. In this Special Issue, we will publish reviews and original research that provide new insights into signaling pathways and biomarkers driving pituitary tumorigenesis, diagnosis, and therapeutic perspectives. Articles about aggressive pituitary adenomas will be particularly welcomed.

Guest Editor

Prof. Dr. Monica Fedele

CNR—Institute of Experimental Endocrinology and Oncology, 80131 Naples, Italy

Deadline for manuscript submissions

closed (30 September 2019)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/19257

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)